EP Patent

EP3738593A1 — Dosing of kras inhibitor for treatment of cancers

Assigned to Amgen Inc · Expires 2020-11-18 · 5y expired

What this patent protects

Provided herein are methods of administering a KRAS G12C inhibitor, namely AMG-510, to a cancer subject.

USPTO Abstract

Provided herein are methods of administering a KRAS G12C inhibitor, namely AMG-510, to a cancer subject.

Drugs covered by this patent

Patent Metadata

Patent number
EP3738593A1
Jurisdiction
EP
Classification
—
Expires
2020-11-18
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.